All In Biotech

Drug Trial Radar · NCT04045769

A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Aug 19, 2019

Primary completion

Nov 27, 2019

Study completion Dec 2, 2019

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

Conditions

  • Healthy

Interventions

  • Saroglitazar magnesium 4mgDrug

    1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally

  • PlacebosDrug

    5 tablets of placebo to be administered orally

  • Moxifloxacin 400mgDrug

    1 tablet of 400 mg Moxifloxacin to be administered orally

  • Saroglitazar magnesium 20 mgDrug

    5 tablets of 4 mg Saroglitazar magnesium to be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QTcF change-from-baselineTime frame: Pre-dose (-1.0 hr) to 24 hours post dose
  2. Saroglitazar and its metabolite saroglitazar sulfoxide plasma concentrations and placebo-corrected change-from-baseline QTcFTime frame: Pre-dose (-1.0 hr) to 24 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliantha Research Limited

    Ahmedabad, Gujarat, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.